AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions

RecruitingPhase 4Ages 65 Years - anyAllYale University
💬

In plain words

What the trial is, and whether it could suit you

To establish the effectiveness and tolerability of standard of care anti-anginal treatment (beta-blocker and calcium channel blocker medications) in older adults with symptomatic Stable Ischemic Heart Disease (SIHD) and multiple chronic conditions (MCC).

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: OLDER ADULTS WITH SIHD AND MCC * Age ≥65 years * ≥ 2 Multiple Chronic Conditions as defined by Centers for Medicare and Medicaid Services (CMS) * Diagnosis of Symptomatic Stable Ischemic Heart Disease with plans to initiate medical therapy identified by at least one of the following: 1. positive non-invasive functional or anatomic testing suggestive of obstructive coronary artery disease 2. coronary angiography with stenosis ≥70% in a coronary artery ≥2 mm in diameter or ≥50% stenosis of left main 3. Invasive coronary angiography with positive physiologic testing in at least one vessel (FFR ≤ 0.80 or iFR ≤0.89) CAREGIVERS * Age ≥ 18 years * Identified as caregiver of LIVEBETTER participant Exclusion Criteria: OLDER ADULTS WITH SIHD AND MCC * Current taking (both) a beta-blocker AND a calcium channel blocker\* * Contraindication to beta-blockers or calcium channel blockers including: 1. significant hypotension 2. high grade AV block 3. severe symptomatic bradycardia 4. severe obstructive lung disease * Documented intolerance to beta-blockers or calcium channel blockers * Probable or definite high-risk coronary artery disease including unrevascularized left main disease and/or unrevascularized multi-vessel disease including the proximal left anterior descending (LAD) artery with plans for immediate complete revascularization * Plans for complete revascularization within 2 weeks * Clear clinical indication for beta-blockers or calcium channel blockers that precludes dose adjustment or crossover: 1. Diagnosis of acute coronary syndrome (ACS) with reduced ejection fraction within past year 2. Heart failure with reduced ejection fraction (HFrEF) within past year * Actively participating in another clinical trial involving an investigational medication or device * Primary language other than English or Spanish * Inability to complete follow-up (e.g. life expectancy \<12 months, impaired decision-making determined by validated instrument) * Previously enrolled in LIVEBETTER * Refused informed consent CAREGIVERS * Professional caregiver (i.e. not a relative or close friend of the participant) * Primary language other than English or Spanish * Inability to complete follow-up * Previously enrolled in LIVEBETTER * Refused informed consent
💊

What it tests

  • Clinician Discretion
  • Beta blocker
  • Calcium channel blocker
📍

Where

10 sites
Yale School of Medicine
New Haven, United States
Wellstar Research Institute
Marietta, United States
Cook County Health
Chicago, United States
Brigham and Women's Hospital
Boston, United States
Mt. Sinai Health System
New York, United States
NYC Health and Hospitals, Harlem Hospital
New York, United States
Nirvana Integrative Medicine
New York, United States
Duke University, School of Medicine
Durham, United States

…and 2 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy